Clinical Trials
2 trialsNCT03516279 2026-04-03
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02767934 2020-08-20
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Terminated